Why Teva Pharmaceuticals (TEVA) Crashed on Wednesday?

In This Article:

We recently published a list of These 10 Stocks Were Wednesday’s Worst Performers. In this article, we are going to take a look at where Teva Pharmaceutical Industries Limited (NYSE:TEVA) stands among Wednesday’s worst-performing stocks.

The stock market declined on Wednesday, with all major indices finishing in the red, driven by losses in technology stocks.

The Nasdaq dropped 0.51%, while the S&P 500 and Dow Jones fell 0.47% and 0.31%, respectively.

Ten companies, mostly from the technology sector, led the downturn.  In this article, we will highlight the biggest decliners and examine the factors driving their performance.

To identify Wednesday’s biggest losers, we focused on stocks with a market capitalization of at least $2 billion and a daily trading volume of over $5 million.

Why Teva Pharmaceuticals (TEVA) is Crashing?
Why Teva Pharmaceuticals (TEVA) is Crashing?

A close-up shot of various types of medicines on a table, illustrating the specialty and generic products offered by the pharmaceutical company.

Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Teva Pharmaceuticals’ share prices declined by 13.89 percent on Wednesday to finish at $18.54 each after announcing disappointing earnings guidance for 2025.

Prior to market opening, Teva (NYSE:TEVA) announced a 3.8-percent increase in revenues to $16.5 billion from the $15.9 billion year-on-year fueled by strong sales in medications for migraines, Huntington’s disease, and schizophrenia.

However, Teva Pharmaceuticals (NYSE:TEVA) expected lower projections for earnings per share for the year at between $2.35 to $2.65 versus the $2.76 projected by analysts.

According to analysts, the positive revenue growth was not enough to outweigh guidance for 2025.

Teva, however, said it remains committed to its “Pivot to Growth” strategy, emphasizing a reorganization and a strengthened focus on generic medications.

In addition, it plans to resume research and development efforts, particularly in key drugs for ulcerative colitis and Crohn’s disease which it expects to be pivotal in shaping the company’s growth trajectory.

Overall, TEVA ranks 2nd on our list of Wednesday’s worst-performing stocks. While we acknowledge the potential of TEVA as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than TEVA but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock.

READ NEXT: 20 Best AI Stocks To Buy Now and Complete List of 59 AI Companies Under $2 Billion in Market Cap

Disclosure: None. This article is originally published at Insider Monkey.